| Literature DB >> 28970893 |
Qingbo Zhang1, Huixian Li1,2, Lu Yu3,4, Yu Sun5, Yiguang Zhu1, Hanning Zhu1, Liping Zhang1, Shu-Ming Li6, Yuemao Shen7, Changlin Tian3,4, Ang Li5, Hung-Wen Liu8, Changsheng Zhang1.
Abstract
Flavoenzymes are ubiquitous in biological systems and catalyze a diverse range of chemical transformations. The flavoenzyme XiaK from the biosynthetic pathway of the indolosesquiterpene xiamycin A is demonstrated to mediate the in vivo biotransformation ofEntities:
Year: 2017 PMID: 28970893 PMCID: PMC5613243 DOI: 10.1039/c7sc01182b
Source DB: PubMed Journal: Chem Sci ISSN: 2041-6520 Impact factor: 9.825
Fig. 1The proposed biosynthetic pathway of XMA (1) and the XiaK-mediated formation of XMA analogues.
Fig. 2HPLC analysis of the production profiles of different strains (A) and the in vivo biotransformation of XMA (1) by XiaK (B). (i) S. coelicolor YF11/pCSG2671 harboring the intact XMA-gene cluster; (ii) control strain YF11/pSET152; (iii) the wild strain S. pactum SCSIO 02999; (iv) standards 1 and 7–11; (v) XMA (1) fed to control strain E. coli BL21(DE3)/pET28a; (vi) XMA (1) fed to E. coli BL21(DE3)/pCSG2607; (vii) XMA (1) fed to control strain S. coelicolor YF11/pPWW50A; (viii) XMA (1) fed to YF11/pCSG2701. Please see note 34 for the symbols “” and “■”.
Fig. 3The in vitro characterization of XiaK. (A) HPLC analysis of the in vitro XiaK enzyme activity assays. A typical XiaK assay was performed in 50 mM Na2HPO4–NaH2PO4 buffer (pH 8.0) for 2 h at 30 °C, comprising 300 μM XMA (1), 1 mM NADPH (or NADH), 1 mM FAD and 5 μM XiaK: (i) XMA (1) standard; (ii) XMA (1) + FAD + NADPH; (iii) XMA (1) + XiaK + FAD; (iv) XMA (1) + XiaK + FAD + NADPH; (v) XMA (1) + XiaK + FAD + NADH; (vi) XMA (1) + XiaK + NADPH; (vii) OXM (7) standard. (B) HPLC analysis of reactions with TMSCHN2. (viii) 12 std; (ix) 12 incubated with TMSCHN2 for 2 h; (x) 1 std; (xi) 1 incubated with TMSCHN2 for 2 h; (xii) an enzyme assay comprising 5 μM XiaK, 0.5 mM 14 and 1 mM NADPH; (xiii) organic extracts from (xii) incubated with TMSCHN2 for 2 h; (xiv) the reaction solution from (xiii) was heated for 2 h, and the conversion of 15 to 14 was observed; (xv) the conversion of 13 to 14 via zinc reduction. (C) Scheme for the chemical transformations of XMA (1) and 12 mediated by XiaK or TMSCHN2.
Fig. 7The proposed mechanism for the formation of diverse chemical bonds and the biosynthesis of OXM (7).
Fig. 4EPR spectra of 12 (as a powder, in acetone, and in MeOH), OXM (7) (in acetone), and 15N-12 (in MeOH), measured at room temperature.
Fig. 5Determination of XiaK kinetic parameters for the substrate 1 ranging from 5 to 200 μM.
Fig. 6Time course of the XiaK reaction and stabilities of XiaK products. (A) HPLC analysis of the time course assay of an in vitro XiaK reaction: (i) 0 min (before adding XiaK); (ii) 5 min; (iii) 10 min; (iv) 15 min; (v) 20 min; (vi) 30 min; (vii) 1 h; (viii) 2 h; (ix) 4 h; (x) 8 h; (xi) 24 h; (xii) 5 days; (xiii) 12 days; (xiv) 1 and 17 standards. (B) Chemical structures of XMA analogues. (C) Stability of 12 dissolved in 50 mM Na2HPO4–NaH2PO4 buffer (pH 8.0): (xv) –20 °C for 2 days; (xvi) –20 °C for 4 days; (xvii) room temperature (RT) for 2 days; (xviii) RT for 4 days; (xix) 60 °C for 2 days; (xx) 60 °C for 4 days; (xxi) XMA (1) standard. The filled black circles () denote multiple XMA-related products which were not isolated for structure elucidation. (D) Stability of OXM (7) treated under various conditions: (xxii) OXM (7) dissolved in 50 mM Na2HPO4–NaH2PO4 buffer (pH 8.0) and incubated at 60 °C for 4 days; (xxiii) 7 dissolved in H2O/MeCN (1 : 1, v/v) and incubated at 60 °C for 4 days; (xxiv) 7 dissolved in MeOH and incubated at 60 °C for 4 days. (E) Stability of 16: (xxv) a complete XiaK assay at 28 °C for 6 h; (xxvi) 16 isolated from an analytical XiaK assay (in trace xxv) immediately used for HPLC analysis; (xxvii) NOXM (12) isolated from an analytical XiaK assay (in trace xxv) immediately used for HPLC analysis.